Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Familact probiotic for nonalcoholic fatty liver disease
IRCT2014112019554N2Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Jun 2015
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of FamiLact in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Zanjan University of Medical Sciences. Started Jun 2015; status: completed.
02
Drugs
FamiLact
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on IRCT2014112019554N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2014112019554N2.